| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.16 | 0.0006 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.089 | 0.05 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.091 | 0.08 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.086 | 0.08 |